Pharmaceutical Executive-12-01-2017

Pharmaceutical Executive

First Foray into Digital Adherence

December 13, 2017

From the Editor

37

12

FDA's approval of the first-ever digital medicine, while sparking legitimate concerns around ethics and trust, could signal improvements ahead to the much-chronicled woes in drug adherence and compliance.

A Year of Transformation for Science & Medicine

December 11, 2017

Columns

37

12

In 2017, patients gained access to the first gene therapies and more orphan and breakthrough drugs.

Fulfilling the Vision of Science: AstraZeneca's Ruud Dobber

December 10, 2017

Features

37

12

Drawing from his research roots and the leadership lessons gained in melding business and culture in geographies across the globe, Ruud Dobber is busy steering AstraZeneca’s US course as it navigates the complexities of a fast-evolving therapeutic market.

Country Report: Canada

December 01, 2017

Special Sponsored Section

37

12

Despite having the tenth-largest pharma market in the world and being the birthplace of medical breakthroughs, from insulin to stem cells, Canada seems to be punching below its weight when it comes to health innovation. There are signs, however, that things may be changing as the nation looks to bulk back up.

Pharmaceutical Executive, December 2017 Issue (PDF)

December 01, 2017

Issue PDF

37

12

Click the title above to open the Pharmaceutical Executive December 2017 issue in an interactive PDF format.